A5028388018- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Renal cell carcinoma treatment
- Inflammatory Biomarkers in Disease Prognosis
- Urinary and Genital Oncology Studies
- Multiple and Secondary Primary Cancers
- Reproductive Health and Technologies
- Economic and Financial Impacts of Cancer
- Retinal and Optic Conditions
- COVID-19 Clinical Research Studies
- Sexual Differentiation and Disorders
- Ocular Oncology and Treatments
- Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Glaucoma and retinal disorders
- Nutrition and Health in Aging
- Long-Term Effects of COVID-19
- Diabetes and associated disorders
- Pancreatic and Hepatic Oncology Research
- COVID-19 and healthcare impacts
- Cancer Genomics and Diagnostics
- Traumatic Ocular and Foreign Body Injuries
- Lung Cancer Treatments and Mutations
- SARS-CoV-2 and COVID-19 Research
- Cerebral Venous Sinus Thrombosis
Columbia University
2024-2025
Columbia University Irving Medical Center
2024
Penn Presbyterian Medical Center
2024
Emory University
2018-2023
Winship Cancer Institute
2019
Background Optimal prognostic and predictive biomarkers for patients with advanced‐stage cancer who received immunotherapy (IO) are lacking. Inflammatory markers, such as the neutrophil‐to‐lymphocyte ratio (NLR), monocyte‐to‐lymphocyte (MLR), platelet‐to‐lymphocyte (PLR), readily available. The authors investigated association between these markers clinical outcomes of IO. Methods A retrospective review was conducted 90 advanced treatment on phase 1 trials IO‐based regimens. NLR, MLR, PLR...
Selecting the appropriate patients to receive immunotherapy (IO) remains a challenge due lack of optimal biomarkers. The presence liver metastases has been implicated as poor prognostic factor in with metastatic cancer. We investigated association between sites disease and clinical outcomes receiving IO. conducted retrospective review 90 treated on IO-based phase 1 trials at Winship Cancer Institute Emory University 2009 2017. Overall survival (OS) progression-free (PFS) were measured from...
Body mass index (BMI) is used to define obesity, but it an imperfect measure of body composition. In the current study, authors explored association between types fat and survival in patients treated with immunotherapy.A retrospective analysis 90 who were immunotherapy on phase 1 clinical trials at Winship Cancer Institute Atlanta, Georgia, from 2009 through 2017 was performed. Overall (OS) progression-free (PFS) outcomes. Baseline BMI radiographic images middle third lumbar vertebrae...
Abstract Background Sarcopenia and inflammation have been associated with poor survival in patients cancer. We explored the combined effects of these variables on cancer treated immunotherapy. Methods performed a retrospective review 90 enrolled immunotherapy-based phase I clinical trials at Emory University from 2009 to 2017. Baseline neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte platelet-to-lymphocyte ratio (PLR) were used as surrogates inflammation. The skeletal muscle index...
Introduction: Retinal pigment epithelial detachment (PED) is an uncommon finding associated with choroidal nevi. In this case series, we describe PED overlying a nevus in four patients and discuss the clinical significance of diagnosis. Case Presentations: Four female patients, aged 55 to 78 years, diagnosed unilateral nevi PEDs were followed over time. Two referred for evaluation due concerns about potential growth. Fundus photography, B-scan ultrasonography, optical coherence tomography...
This case report highlights a temporal relationship between the use of glucagon-like peptide-1 receptor (GLP-1) agonist and occurrence central retinal artery occlusion.
Several immune checkpoint inhibitors (ICIs) are approved for the treatment of advanced urothelial carcinoma (UC). There limited biomarkers ICI-treated patients with UC. We investigated association between body composition and clinical outcomes in UC patients.We conducted a retrospective analysis 70 at Winship Cancer Institute from 2015 to 2020. Baseline computed tomography images within 2 months ICI initiation were collected mid-L3 muscle fat compartments (subcutaneous, intermuscular,...
Abstract Background The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria are the gold standard for risk-stratifying patients with metastatic renal cell cancer (mRCC). We developed a novel risk scoring system mRCC treated immune checkpoint inhibitors (ICIs). Methods performed retrospective analysis of 100 ICI-treated at Winship Cancer Institute from 2015 to 2018. Several baseline variables were collected, including markers inflammation, body mass index (BMI),...
The modified Glasgow prognostic score (mGPS), a clinical tool that incorporates albumin and C-reactive protein, has proven useful in the prognostication of multiple cancers. Several immune checkpoint inhibitors (ICIs) have been approved for treatment metastatic urothelial cell carcinoma (mUC), but biomarker is needed. We investigated impact mGPS on survival outcomes patients with mUC receiving ICIs.We retrospectively reviewed treated ICIs (programmed death protein 1 or programmed ligand...
To determine clinical course and outcomes in rheumatic disease patients with coronavirus 2019 (COVID-19) compare results to uninfected patients.
In advanced urothelial cancers (UC), immune checkpoint inhibitors (ICI) show promise as a durable therapy. Immune-related adverse events (irAEs), side effect of ICIs, may serve an indicator beneficial response. We investigated the relationship between irAEs and clinical outcomes in patients with UC who received ICI.In this retrospective study, we 70 treated ICIs at Winship Cancer Institute from 2015 to 2020. Data on were collected through chart review. Cox's proportional hazard model...
Background The modified Glasgow Prognostic Score (mGPS) is a composite biomarker that uses albumin and C reactive protein (CRP). There are multiple immune checkpoint inhibitor (ICI)-based combinations approved for metastatic renal cell carcinoma (mRCC). We investigated the ability of mGPS to predict outcomes in patients with mRCC receiving ICI. Methods retrospectively reviewed treated ICI as monotherapy or combination at Winship Cancer Institute between 2015 2020. Overall survival (OS)...
We analyzed disease outcomes for patients with diabetes and laboratory-confirmed COVID-19 who were managed outpatient followed by the Emory Virtual Outpatient Management Clinic (ECVOMC). The rate of hospitalization was double overall in ECVOMC.
We developed a novel risk scoring system for urothelial cancer (UC) patients receiving immune checkpoint inhibitors (ICI).We conducted retrospective review of 67 UC treated with ICI at Winship Cancer Institute Emory University from 2015 to 2018. Using stepwise variable selection in Cox proportional hazard model and Sullivan's weighting schema, baseline platelet-to-lymphocyte ratio (PLR), presence liver metastasis, albumin, Eastern Cooperative Oncology Group performance status (ECOG PS) were...
472 Background: The increasing use of IO agents in the treatment urothelial cancer has revealed irAEs during therapy. We investigated whether there is an association between treatment-related and CO pts treated with IO. Methods: performed a retrospective analysis 67 PD-1/PD-L1 inhibitors at Winship Cancer Institute from 2015-2018. Overall survival (OS) progression free (PFS) were calculated first dose to date death or hospice referral clinical radiographic progression, respectively....
ABSTRACT Objectives To determine clinical course and outcomes in rheumatic disease patients with coronavirus 2019 (COVID-19) compare results to uninfected patients. Methods We conducted a case cohort study of autoimmune COVID-19 (confirmed by severe acute respiratory syndrome 2 PCR) from 02/01/2020 07/31/2020 compared them 1:3 ratio who were matched based on race, age, sex, comorbidity index. Patient demographics, course, among these patient groups. Results A total 70 (mean 56.6 years; 64%...
613 Background: BMI has been explored as a prognostic factor in cancer pts and treatment-related toxicities have associated with responses to VEGF-targeted therapy mRCC pts. We investigated the association of adverse events (AEs) CO treated cabo. Methods: A retrospective analysis 65 cabo at Winship Cancer Institute from 2016 2018 was performed. Overall survival (OS), progression-free (PFS), objective response (OR) were used measure CO. OS PFS calculated first dose death radiographic or...
In concordance with medical recommendations in response to COVID-19, Emory Healthcare limited surgical procedures starting March 16, 2020. We investigated the impact of these on number, types, and urgency retina cases.We conducted a retrospective review all patients at Retina division Eye Center from February 17-April 12, 2020 during same time period 2019 2018. The demographics types surgeries were collected. Descriptive statistics for each variable reported. Univariate analysis was carried...
Cabozantinib is an effective treatment for metastatic renal cell carcinoma (mRCC). The international mRCC database consortium (IMDC) criteria the gold standard risk stratification in mRCC. We created a scoring system specific patients treated with cabozantinib. conducted retrospective review of 87 cabozantinib at Winship Cancer Institute from 2015 to 2019. Overall survival (OS) and progression free (PFS) were used measure clinical outcomes. Upon variable selection multivariable analysis...
We present a novel case of intraosseous venous malformation the frontal bone with dehiscence inner table calvarium and extension into sinus orbit. This report discusses surgical management this lesion achieved multidisciplinary approach involving otolaryngology neurosurgical teams. also review literature pathophysiology malformations, imaging modalities that aid in diagnosis these lesions options.